CALZF Stock UPDATES Calzada Limited (CALZF) 0.0850 08/30/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Calzada Limited (CALZF) 0.0850 $CALZF

Cartilage Degeneration - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/hzb6kb/cartilage) has announced the addition of the "Cartilage Degeneration - Pipeline Review, H2 2013" report to their offering. 'Cartilage Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cartilage Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cartilage Degeneration. Scope - A snapshot of the global therapeutic scenario for Cartilage Degeneration. - A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cartilage Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cartilage Degeneration Overview Therapeutics Development Clinical Stage Products Early Stage Products Cartilage Degeneration - Products under Development by Companies Cartilage Degeneration - Companies Involved in Therapeutics Development Cartilage Degeneration - Therapeutics Assessment Drug Profiles sprifermin - Drug Profile Chondrogen - Drug Profile MSB-CAR-001 - Drug Profile AOD-9604 - Drug Profile THR-166 - Drug Profile ST-03 - Drug Profile Cartilage Degeneration - Recent Pipeline Updates Appendix List of Tables List of Figures Companies Mentioned Sanofi Merck KGaA Mesoblast Limited Calzada Limited Thrasos, Inc. For more information visit http://www.researchandmarkets.com/research/hzb6kb/cartilage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Osteoporosis - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Osteoporosis
M2 - Tue Sep 03, 9:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9tgmch/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Osteoporosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoporosis. Scope - A snapshot of the global therapeutic scenario for Osteoporosis. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoporosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Affectis Pharmaceuticals AG Amgen Inc. B&C Biopharm Biodel Inc. Bone Medical Limited Calzada Limited Critical Pharmaceuticals Limited DONGKOOK Pharmaceutical Co., Ltd. Dongwha Pharm Co., Ltd. Eli Lilly and Company EndoCeutics, Inc. Ensoltek Co., Ltd. F. Hoffmann-La Roche Ltd. Galapagos NV HYUNDAI PHARM. CO., LTD. Hindustan Latex Limited IMMD Inc. Kaken Pharmaceutical Co.,Ltd. Merck & Co., Inc. NeoStem, Inc. Novartis AG Oscotec Inc. Pfizer Inc. Radius Health, Inc. Siena Biotech S.p.A. TSRL, Inc. Uni-Bio Science Group Ltd. Ventria Bioscience Zelos Therapeutics, Inc. Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/9t...teoporosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Bone Disorders - Pipeline Review, H1 2013
M2 - Fri Mar 22, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lqxhlr/bone_disorders) has announced the addition of the "Bone Disorders - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Bone Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Disorders. Scope - A snapshot of the global therapeutic scenario for Bone Disorders. - A review of the Bone Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherap




Scroll down for more posts ▼

Top 10 Most Recent News Articles

IBM's Sports Tech Challenge Crowns AI Innovator LivXP

Updated Category News Views 18

Pioneering AI for Fan Engagement The big leagues of sports tech are buzzing, as IBM has just announced LivXP as the standout winner of their Sports Tech Startup Prize Challenge at the dynamic Web Summit Lisbon 2026. If there's one thing to remember, it's that this isn't just any accolade. This is a nod from IBM—an institution that's rubbed elbows with the giants of...

Continue Reading
Skilled Nursing: The Backbone of Comprehensive Care

Updated Category News Views 17

Crucial Crossroads: Hospital to Home Some stories don't come with ticker symbols or stock rises. Sometimes, we're sifting through what really matters—like Terry Esterline's rundown on skilled nursing and rehab services in Hillsdale, Michigan. This isn't about making a quick buck, it's about what helps people rebuild after a hospital stay. The Nuts and Bolts of Skilled...

Continue Reading
Nauticus Schedules 2026 Q3 Earnings Call; Key Insights Await

Updated Category News Views 100

Word on the street is that Nauticus Robotics is gearing up to dish out their third quarter earnings on November 17, 2026. If you're eyeballing the stock, NASDAQ:KITT, this might be your show. Autonomy in the subsea world isn't just about flashy tech—it's about getting investors to buy into the vision. These folks are turning waves into action with robots that perform...

Continue Reading
HLTH 2026: AI's Role in Couples Therapy Unveiled

Updated Category News Views 14

Testing AI's Place in the Therapy Room AI's getting more action in therapy sessions than it ever dreamed, and it’s high time we asked who benefits and who loses. Slotting in next to human therapists, AI like OurRitual’s Ora isn't about to steal the whole show, but it sure knows how to play a supporting role. At the HLTH 2026 conference, Dr. Orna Guralnik and OurRitual...

Continue Reading
DAN, GPRO, PSNL Deals Under Investor Scrutiny

Updated Category News Views 266

Behind the Curtain: What Do These Deals Mean for Shareholders? Sometimes, investing in a stock ain't just about numbers on a screen—it's about untangling the whole messy ball of yarn these companies hand you with a smile. We're looking at Dana Incorporated (NYSE: DAN), GoPro, Inc. (NASDAQ: GPRO), and Personalis, Inc. (NASDAQ: PSNL). They've all got deals on the table,...

Continue Reading
Baidu Faces Securities Suit Deadline This Week

Updated Category News Views 74

Deadline Looms Large for Baidu Investors Well, here we are again, dealing with another securities class action. If you've got your money parked in Baidu (NASDAQ:BIDU), the clock is ticking, and it's time to pay attention. November 13, 2026, is creeping up fast, and that could be a serious point of no return. What's the Buzz About? Faruqi & Faruqi, LLP, a heavyweight in...

Continue Reading
FIS Under Investigation: Legal Woes Hit Shareholders

Updated Category News Views 55

When Forecasts Falter: A Reality Check for FIS Investors You ever get the feeling a company is just a bit too optimistic? Well, Fidelity National Information Services, Inc. (NYSE: FIS) might've been playing that game up until its recent fiscal hiccup. The mess started on November 4, 2026, when FIS decided to slash its fiscal 2026 adjusted EPS outlook. From a Wall Street...

Continue Reading
Millrose Faces Class Action for Alleged Deception

Updated Category News Views 124

A Surprising Turn for Millrose Properties Nobody's grumbling over their coffee as much as Millrose Properties' investors these days. The company, traded under NYSE:MRP, is facing a securities class action lawsuit that'll make even the steeliest fund managers flinch. You see, this isn't just any lawsuit—it's a slap in the face of those who thought they were backing a...

Continue Reading
Frasle Mobility's Resilience Despite Market Woes in 3Q26

Updated Category News Views 125

Economic Wrangling: What Happened? Here comes Frasle Mobility, standing tall against a tide trying to pull everyone under. Ending the third quarter of 2026, they dropped a modest net revenue of R$1.38 billion. A light dip of 1.9% year-over-year, but don't let that fool you. Amid the chaos, these folks managed to expand their gross margin and kept their financials...

Continue Reading
MY DR NOW Challenges 9-to-5 with New Clinics

Updated Category News Views 12

Revolutionizing Healthcare Access Latte in one hand and the other hand tapping your steering wheel, trying to squeeze in that elusive doctor’s appointment between work meetings. Sound familiar? Well, those days might just be numbered. MY DR NOW is shaking up the traditional 9-to-5 doctor’s office stereotype by opening two new clinics that’ll stand sentinel seven...

Continue Reading

Top 5 Most Recently Viewed Articles

Immunocore Unveils Promising Data for Brenetafusp in Ovarian Cancer

Updated Category News Views 129

Immunocore Takes Key Steps with Brenetafusp Immunocore, a biotechnology firm dedicated to creating innovative immunomodulating treatments, has revealed important findings from the Phase 1 trials of brenetafusp, an ImmTAC bispecific that targets PRAME in ovarian cancer patients who are resistant to platinum therapy. These results were shared at a notable medical...

Continue Reading
Santhera and Ikris Pharma Join Forces for AGAMREE® in India

Updated Category News Views 216

Santhera Partners with Ikris for AGAMREE® Distribution Pratteln, Switzerland – Santhera Pharmaceuticals (SIX: SANN) has recently formed a pivotal agreement with Ikris Pharma Network to distribute AGAMREE® (vamorolone) in India. This exclusive partnership is dedicated to providing a treatment option for Duchenne muscular dystrophy (DMD) in children four years and...

Continue Reading
Orchid Island Capital Highlights August Dividend and Portfolio Insights

Updated Category News Views 183

Orchid Island Capital Declares August Monthly Dividend Orchid Island Capital, Inc. (NYSE: ORC), a prominent player in the specialized finance sector, has declared a monthly cash dividend of $0.12 per common share for August. This dividend is scheduled for distribution on September 29, keeping with the company’s commitment to returning value to its shareholders. Dividend...

Continue Reading
Mercari Japan App Debuts in U.S.: A Shopping Shift

Updated Category News Views 15

A New Frontier for Cross-Border Shopping There's a fresh wind blowing for collectors and Japan enthusiasts in the U.S. as Mercari Japan rolls out a new standalone app on American soil. Designed to streamline the hunt for Japanese treasures, it’s a bold play to solidify Mercari’s position as a cross-border e-commerce powerhouse. Maybe they’ve seen the writing on the...

Continue Reading
Franklin Access Receives Financing for Groundbreaking Sigbeat Venture

Updated Category News Views 195

Franklin Access Secures New Funding for Innovative Sigbeat Joint Venture Franklin Access (NASDAQ: FKWL) is thrilled to announce that it has successfully secured funding for its strategic joint venture to develop cutting-edge 4G/5G modules and artificial intelligence (AI) solutions under the Sigbeat brand. This significant milestone marks a transformative step towards...

Continue Reading